ReviewJournal of cellular physiology2009
Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.
Review in Journal of cellular physiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 118 citations in OpenAlex.
- Review
- Promising Strategy of mPTP Modulation in Cancer Therapy: An Emerging Progress and Future Insight.International journal of molecular sciences · 2023Review
- Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond.Current issues in molecular biology · 2023Review
- AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma.Cancers · 2023Article
- Hypericin, a potential new BH3 mimetic.Frontiers in pharmacology · 2022Article
- The role of long non-coding RNAs in mediating chemoresistance by modulating autophagy in cancer.RNA biology · 2020Article
- Natural Agents Targeting Mitochondria in Cancer.International journal of molecular sciences · 2020Review
- Anionic Polymers Promote Mitochondrial Targeting of Delocalized Lipophilic Cations.Bioconjugate chemistry · 2020Article
- Measles virus phosphoprotein inhibits apoptosis and enhances clonogenic and migratory properties in HeLa cells.Journal of biosciences · 2019Article
- Targeting mitochondria in cancer: current concepts and immunotherapy approaches.Translational research : the journal of laboratory and clinical medicine · 2018Review
- Article
- Inhibition of the oncogenic fusion protein EWS-FLI1 causes GScience signaling · 2017Article
- The Gαi-GIV binding interface is a druggable protein-protein interaction.Scientific reports · 2017Article
- Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Antitumor Activity as an Inhibitor of Antiapoptotic Proteins.ACS medicinal chemistry letters · 2016Article
- Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.British journal of pharmacology · 2016Article
- The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells.Cancer cell international · 2016Article
- Broad targeting of resistance to apoptosis in cancer.Seminars in cancer biology · 2015Review
- Selecting efficacious Bcl-2 family inhibitors for optimal clinical outcome.Annals of translational medicine · 2015Article
- Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells.Journal of experimental & clinical cancer research : CR · 2015Article
- Inhibitory activity of apogossypol in human prostate cancer in vitro and in vivo.Molecular medicine reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A critical regulator of the apoptotic machinery is the Bcl-2 family proteins whose over expression confers a protective effect on malignant cells against death signals of apoptosis. Cancer cells that are resistant to various anti-cancer drugs and treatment regimen are found to over express these Bcl-2 proteins such as Bcl-2, Bcl-X(L), Mcl-1, Bcl-w, and A1/Bfl1. In recent years there has been an exponential growth in the identification as well as synthesis of non-peptidic cell permeable small-molecule inhibitors (SMIs) of protein-protein interaction. The focus of this article is on inhibitors of anti-apoptotic protein Bcl-2. This review summarizes an up to date knowledge of the available SMIs, their mode of action as well as their current status in preclinical as well as clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.